Market closed
ESSA Pharma/$EPIX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ESSA Pharma
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Ticker
$EPIX
Sector
Trading on
Industry
Biotechnology
Headquarters
Vancouver, Canada
Employees
50
Website
ESSA Pharma Metrics
BasicAdvanced
$76M
Market cap
-
P/E ratio
-$0.63
EPS
1.83
Beta
-
Dividend rate
Price and volume
Market cap
$76M
Beta
1.83
52-week high
$11.67
52-week low
$1.40
Average daily volume
1.5M
Financial strength
Current ratio
36.948
Quick ratio
36.609
Long term debt to equity
0.178
Total debt to equity
0.266
Interest coverage (TTM)
-30,218.60%
Management effectiveness
Return on assets (TTM)
-14.79%
Return on equity (TTM)
-19.83%
Valuation
Price to book
0.59
Price to tangible book (TTM)
0.59
Price to free cash flow (TTM)
-3.171
Growth
Earnings per share change (TTM)
0.60%
3-year earnings per share growth (CAGR)
-12.97%
What the Analysts think about ESSA Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ESSA Pharma stock.
ESSA Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ESSA Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ESSA Pharma News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ESSA Pharma Inc. (EPIX) and Encourages Shareholders to Learn More About the Investigation
Accesswire·2 days ago
EPIX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc.
Accesswire·3 days ago
ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Accesswire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ESSA Pharma stock?
ESSA Pharma (EPIX) has a market cap of $76M as of November 08, 2024.
What is the P/E ratio for ESSA Pharma stock?
The price to earnings (P/E) ratio for ESSA Pharma (EPIX) stock is 0 as of November 08, 2024.
Does ESSA Pharma stock pay dividends?
No, ESSA Pharma (EPIX) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next ESSA Pharma dividend payment date?
ESSA Pharma (EPIX) stock does not pay dividends to its shareholders.
What is the beta indicator for ESSA Pharma?
ESSA Pharma (EPIX) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.